In a session at this year’s Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria, researchers...

Morphic Medical has announced that the first commercial patient has been treated with RESET, the company’s therapy designed to target the...

Ascletis Pharma’s ASC47, a muscle-preserving weight loss drug candidate, in combination with semaglutide demonstrated up to 56.2% greater...

Researchers led by Rice University's Yong Lin Kong have developed a soft but strong metamaterial that can be controlled remotely to...

Researchers from the College of Public Health, Temple University, Philadelphia, PA, have warned how some plastic surgeons are promoting...

Metabolic bariatric surgery (MBS) achieves greater weight loss and lower ongoing cost compared to the glucagon-like peptide-1 receptor...

Welcome to our regular round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of orforglipron, an investigational oral glucagon-like...

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight loss,...

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo metabolic and bariatric surgery (MBS)...

A study led by investigators at Mass General Brigham has found that adding semaglutide and tirzepatide to usual care represents a...

Individuals who are taking semaglutide for weight loss experience less food noise than before, according to research presented at the...